Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition

References

• DentRTrudeauMPritchardKITriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res20071315 Pt 14429443417671126
   PubMed Web of Science ®Google Scholar
• [No authors listed]Positive results for drug combo in I-SPY 2 trialCancer Discov201442OF2
   Google Scholar
• HafftyBGYangQReissMLocoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancerJ Clin Oncol200624365652565717116942
   PubMed Web of Science ®Google Scholar
• GuarneriVDieciMVContePRelapsed triple-negative breast cancer: challenges and treatment strategiesDrugs201373121257126523842749
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• PerouCMSørlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• SørlieTPerouCMTibshiraniRGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci U S A20019819108691087411553815
   PubMed Web of Science ®Google Scholar
• HanBAudehWJinYBagariaSCuiXBiology and treatment of basal-like breast cancerSchattenHCell and Molecular Biology of Breast CancerNew YorkSpringer2013
   Google Scholar
• BertucciFFinettiPCerveraNHow basal are triple-negative breast cancers?Int J Cancer2008123123624018398844
   PubMed Web of Science ®Google Scholar
• PratAAdamoBCheangMCAndersCKCareyLAPerouCMMolecular characterization of basal-like and non-basal-like triple-negative breast cancerOncologist201318212313323404817
   PubMed Web of Science ®Google Scholar
• LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
   PubMed Web of Science ®Google Scholar
• OakmanCMorettiEPaciniGSantarpiaLDi LeoATriple negative breast cancer: a heterogeneous subgroup defined by what it is notEur J Cancer201147Suppl 3S370S37221944019
   PubMed Web of Science ®Google Scholar
• LehmannBDPietenpolJAIdentification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypesJ Pathol2014232214215024114677
   PubMed Web of Science ®Google Scholar
• IgnatiadisMA meta-analysis of gene expression profiling studies identifies clinically relevant oncogenic pathways in basal-like breast cancerCancer Res20096924 Suppl 3106
   Web of Science ®Google Scholar
• MasudaHBedardPHaibe-KainsDifferential response to neo-adjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypesClin Cancer Res201319195533554023948975
   PubMed Web of Science ®Google Scholar
• KaramiFMehdipourPA comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancerBiomed Res Int2013201392856224312913
   PubMed Web of Science ®Google Scholar
• HartmanARKaldateRRSailerLMPrevalence of BRCA mutations in an unselected population of triple-negative breast cancerCancer2012118112787279522614657
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAMTimmsKMLiuSIncidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancerClin Cancer Res20111751082108921233401
   PubMed Web of Science ®Google Scholar
• BayraktarSGlückSSystemic therapy options in BRCA mutation- associated breast cancerBreast Cancer Res Treat2012135235536622791366
   PubMed Web of Science ®Google Scholar
• FarmerHMcCabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• BryantHESchultzNThomasHDSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature2005434703591391715829966
   PubMed Web of Science ®Google Scholar
• TurnerNTuttAAshworthAHallmarks of ‘BRCAness’ in sporadic cancersNat Rev Cancer200441081481915510162
   PubMed Web of Science ®Google Scholar
• ChalasaniPLivingstonRDifferential chemotherapeutic sensitivity for breast tumors with “BRCAness”: a reviewOncologist201318890991623881989
   PubMed Web of Science ®Google Scholar
• De SummaSPintoRSambiasiDBRCAness: a deeper insight into basal-like breast tumorsAnn Oncol201324Suppl 8viii13viii2124131964
   PubMed Web of Science ®Google Scholar
• TurnerNMorettiESiclariOTargeting triple negative breast cancer: is p53 the answer?Cancer Treat Rev201339554155023321033
   PubMed Web of Science ®Google Scholar
• LipsEHMulderLOonkATriple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriersBr J Cancer2013108102172217723558900
   PubMed Web of Science ®Google Scholar
• TelliMJensenKCAbkevichVHomologous recombination deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple negative and BRCA1/2 mutation associated breast cancerCancer Res20127224 Suppl 3PD09-04
   Web of Science ®Google Scholar
• TimmsKAbkevichVNeffCMorrisBFrequency of homologous repair defects across breast cancer subtypes2013: Poster presented at: 104th Annual Meeting of the American Association of Cancer ResearchApril 6–10, 2013Washington
   Google Scholar
• RiceJCOzcelikHMaxeinerPAndrulisIFutscherBWMethylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimensCarcinogenesis20002191761176510964110
   PubMed Web of Science ®Google Scholar
• LipsEHMulderLHannemannJIndicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapyAnn Oncol201122487087620937646
   PubMed Web of Science ®Google Scholar
• OonkAMvan RijnCSmitsMMClinical correlates of ‘BRCAness’ in triple-negative breast cancer of patients receiving adjuvant chemotherapyAnn Oncol20122392301230522357256
   PubMed Web of Science ®Google Scholar
• ChambonPWeillJDMandelPNicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzymeBiochem Biophys Res Commun1963111394314019961
   PubMed Web of Science ®Google Scholar
• HelledayTPetermannELundinCHodgsonBSharmaRADNA repair pathways as targets for cancer therapyNat Rev Cancer20088319320418256616
   PubMed Web of Science ®Google Scholar
• SteffenJDBrodyJRArmenRSPascalJMStructural implications for selective targeting of PARPsFront Oncol2013330124392349
   PubMedGoogle Scholar
• RouleauMPatelAHendzelMJKaufmannSHPoirierGGPARP inhibition: PARP1 and beyondNat Rev Cancer201010429330120200537
   PubMed Web of Science ®Google Scholar
• AshworthAA synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repairJ Clin Oncol200826223785379018591545
   PubMed Web of Science ®Google Scholar
• GianniniGBattistuzziGVesciLNovel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffoldBioorg Med Chem Lett201424246246624388690
   PubMed Web of Science ®Google Scholar
• De LorenzoSBPatelAGHurleyRMKaufmannSHThe elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cellsFront Oncol2013322824062981
   PubMedGoogle Scholar
• MuraiJHuangSYDasBBTrapping of PARP1 and PARP2 by clinical PARP inhibitorsCancer Res201272215588559923118055
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYRenaudAStereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparibMol Cancer Ther201413243344324356813
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJOsborneCPippenJEIniparib plus chemotherapy in metastatic triple-negative breast cancerN Engl J Med2011364320521421208101
   PubMed Web of Science ®Google Scholar
• MateoJOngMTanDSGonzalezMAde BonoJSAppraising iniparib, the PARP inhibitor that never was – what must we learn?Nat Rev Clin Oncol2013101268869624129347
   PubMed Web of Science ®Google Scholar
• SinhaGDownfall of iniparib: a PARP inhibitor that doesn’t inhibit PARP after allJ Natl Cancer Inst20141061djt44724402426
   PubMedGoogle Scholar
• PatelAGDe LorenzoSBFlattenKSPoirierGGKaufmannSHFailure of iniparib to inhibit poly(ADP-ribose) polymerase in vitroClin Cancer Res20121861655166222291137
   PubMed Web of Science ®Google Scholar
• PierceAMcGowanPMCotterMComparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell linesCancer Biol Ther201314653754523760496
   PubMed Web of Science ®Google Scholar
• FongPCBossDSYapTAInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med2009361212313419553641
   PubMed Web of Science ®Google Scholar
• AudehMWCarmichaelJPensonRTOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
   PubMed Web of Science ®Google Scholar
• TuttARobsonMGarberJEOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialLancet2010376973723524420609467
   PubMed Web of Science ®Google Scholar
• KaufmanBShapira-FrommerRSchmutzlerRKOlaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: an open-label phase II studyJ Clin Oncol201331Suppl11024
   Google Scholar
• ChanSLMokTPARP inhibition in BRCA-mutated breast and ovarian cancersLancet2010376973721121320656109
   PubMed Web of Science ®Google Scholar
• GelmonKAHirteHWRobidouxACan we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancerJ Clin Oncol201028Suppl 15300220479400
   PubMed Web of Science ®Google Scholar
• ChuangHCKapuriyaNKulpSKChenCSShapiroCLDifferential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cellsBreast Cancer Res Treat2012134264965922678161
   PubMed Web of Science ®Google Scholar
• PalmaJPWangYCRodriguezLEABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumorsClin Cancer Res200915237277729019934293
   PubMed Web of Science ®Google Scholar
• KummarSJiJMorganRA phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomasClin Cancer Res20121861726173422307137
   PubMed Web of Science ®Google Scholar
• IsakoffSJOvermoyerBTungNMA phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancerJ Clin Oncol201028Suppl 151019
   Web of Science ®Google Scholar
• SandhuSKSchelmanWRWildingGThe poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialLancet Oncol201314988289223810788
   PubMed Web of Science ®Google Scholar
• DrewYMulliganEAVongWTTherapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2J Natl Cancer Inst2011103433434621183737
   PubMedGoogle Scholar
• DrewYLedermannAJonesAPhase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancerJ Clin Oncol201129Suppl 153104
   Google Scholar
• ShenYRehmanFLFengYBMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiencyClin Cancer Res201319185003501523881923
   PubMed Web of Science ®Google Scholar
• De BonoJSMinaLAGonzalezMFirst-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumorsJ Clin Oncol201331Suppl 15258023733753
   PubMed Web of Science ®Google Scholar
• CardnellRJByersLAProteomic markers of DNA repair and Pl3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancerClin Cancer Res201319226322632824077350
   PubMed Web of Science ®Google Scholar
• SantarpiaLIwamotoTDi LeoADNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypesOncologist201318101063107324072219
   PubMed Web of Science ®Google Scholar
• PitrodaSPPashtanIMLoganHLDNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapySci Transl Med20146229229ra42
   Web of Science ®Google Scholar
• PengGLinCJMoWGenome-wide transcriptome profiling of homologous recombination DNA repairNat Commun20145336124553445
   PubMed Web of Science ®Google Scholar
• Mendes-PereiraAMMartinSABroughRSynthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Mol Med200916–731532220049735
   PubMed Web of Science ®Google Scholar
• IbrahimYHGarcía-GarcíaCSerraVPI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibitionCancer Discov20122111036104722915752
   PubMed Web of Science ®Google Scholar
• MatulonisUWWolfGMBirrerMJPhase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC)J Clin Oncol201432Suppl 52510
   Web of Science ®Google Scholar
• JohnsonNLiYCWaltonZECompromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNat Med201117787588221706030
   PubMed Web of Science ®Google Scholar
• O’NeilNJvan PelDMHieterPSynthetic lethality and cancer: cohesin and PARP at the replication forkTrends Genet201329529029723333522
   PubMed Web of Science ®Google Scholar
• NowsheenSCooperTStanleyJAYangESSynthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cellsPLoS One2012710e4661423071597
   PubMed Web of Science ®Google Scholar
• DurkaczBWIrwinJShallSInhibition of (ADP-ribose) biosynthesis retards DNA repair but does not inhibit DNA repair synthesisBiochem Biophys Res Commun1981101143314416272786
   PubMed Web of Science ®Google Scholar